ibrutinib
abbvie,janssen
['ibru', 'lymsm']
pod24 is adversely prognostic with induction, and early relapse adversely affects os. this has therapeutic implications, as evidenced by worse os when ibrutinib used in later relapse vs first relapse. #asco22 #lymsm 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????